Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | JAK1 | P23458 | 2/20 | 0.50 |
| ▸ | TYK2 | P29597 | 2/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | CD69 | Q07108 | 2/20 | 0.46 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23276995 | 0.95 | BTK (0.51) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL23312107 | 0.94 | BTK (0.51) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL23312193 | 0.92 | JAK2 (0.51) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL23276927 | 0.90 | JAK2 (0.52) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL24807680 | 0.90 | JAK2 (0.52) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL23276746 | 0.88 | JAK2 (0.50) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL23276817 | 0.87 | JAK1 (0.57) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL24806499 | 0.86 | JAK2 (0.54) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL23312125 | 0.86 | JAK2 (0.48) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL23312111 | 0.85 | BTK (0.51) | BTKJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411408-A1 | Small Molecule Compound | TECHNODERMA MEDICINES INC. (CN) | 2022-12-29 | — | — | US | disclosed |
| CN-110862380-A | Small molecule compound | 嘉兴特科罗生物科技有限公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411408-A1 | Small Molecule Compound | JAK1, JAK2, TYK2 | BTK 211/4885JAK2 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.